The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis.

医学 肉芽肿伴多发性血管炎 抗中性粒细胞胞浆抗体 系统性血管炎 ANCA相关性血管炎 结节性多动脉炎 痹症科 巨细胞动脉炎
作者
Juyoung Yoo,Ho Jae Kim,Sung Soo Ahn,Seung Min Jung,Jason Jungsik Song,Yong Beom Park,Sang Won Lee
出处
期刊:Clinical and Experimental Rheumatology [Springer Vienna]
卷期号:36 (2): 85-87 被引量:18
标识
摘要

Objectives We applied the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis (GPA) to 150 Korean patients with previously diagnosed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and investigated how many patients with AAV were reclassified as GPA. Methods We included patients with 30 GPA, 30 eosinophilic GPA (EGPA) and 90 microscopic polyangiitis (MPA) patients. Patients can be classified as GPA, when the sum of scores is more than 5. Results At diagnosis the mean age of 150 patients with AAV was 60.1 years old, and 101 patients (67.3%) were women. Overall, 33 of 150 patients with AAV (22.0%) were classified as GPA according to the 2017 provisional criteria for GPA. The 2017 provisional criteria for GPA dropped to 10.0% of previously diagnosed GPA patients and the major factor to drop 3 GPA patients was the deletion of 2 items of the 1990 criteria, urinary sediment and infiltrates on chest radiograph. Meanwhile, one of 30 patients with EGPA (3.3%) and 5 of 90 patients with MPA (5.6%) were newly classified as GPA based on the 2017 provisional criteria for GPA. We could also find that items of the 2017 provisional criteria to contribute to reclassifying EGPA and MPA patients as GPA were PR3-ANCA, mass-like lung lesion and nasal congestion in Korean patients with AAV. Conclusions The use of the 2017 provisional criteria for GPA excluded 10.0% of previously classified GPA patients and newly classified 3.3% of EGPA patients and 5.6% of MPA patients as GPA in Korean patients with AAV.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
HJX完成签到,获得积分10
1秒前
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
小白t73完成签到,获得积分10
1秒前
1秒前
JamesPei应助科研通管家采纳,获得10
1秒前
汉堡包应助科研通管家采纳,获得10
1秒前
赘婿应助科研通管家采纳,获得10
1秒前
凪启应助科研通管家采纳,获得10
1秒前
英俊的铭应助科研通管家采纳,获得10
2秒前
夜看枫林晚完成签到,获得积分10
2秒前
zhonglv7应助科研通管家采纳,获得10
2秒前
缓慢夜阑发布了新的文献求助10
2秒前
5476完成签到,获得积分10
2秒前
Orange应助科研通管家采纳,获得10
2秒前
bkagyin应助科研通管家采纳,获得10
2秒前
斯文败类应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
2秒前
zhonglv7应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
Troy完成签到,获得积分10
2秒前
脑洞疼应助科研通管家采纳,获得10
2秒前
慕青应助未来可期采纳,获得10
2秒前
2秒前
zhonglv7应助科研通管家采纳,获得10
2秒前
Twonej应助科研通管家采纳,获得30
3秒前
英姑应助科研通管家采纳,获得10
3秒前
顾矜应助科研通管家采纳,获得10
3秒前
深情安青应助科研通管家采纳,获得10
3秒前
科研小农民完成签到,获得积分10
3秒前
zzrg完成签到,获得积分10
3秒前
3秒前
3秒前
天天快乐应助科研通管家采纳,获得10
3秒前
3秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Burger's Medicinal Chemistry, Drug Discovery and Development, Volumes 1 - 8, 8 Volume Set, 8th Edition 1800
Cronologia da história de Macau 1600
Contemporary Debates in Epistemology (3rd Edition) 1000
International Arbitration Law and Practice 1000
文献PREDICTION EQUATIONS FOR SHIPS' TURNING CIRCLES或期刊Transactions of the North East Coast Institution of Engineers and Shipbuilders第95卷 1000
BRITTLE FRACTURE IN WELDED SHIPS 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 计算机科学 化学工程 生物化学 物理 复合材料 内科学 催化作用 物理化学 光电子学 细胞生物学 基因 电极 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6159794
求助须知:如何正确求助?哪些是违规求助? 7987960
关于积分的说明 16602496
捐赠科研通 5268201
什么是DOI,文献DOI怎么找? 2810869
邀请新用户注册赠送积分活动 1791001
关于科研通互助平台的介绍 1658101